AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22089958 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile neurofeedback training (15 min daily for 2 weeks)
Number of subjects: 105
Study 22089958 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 105
Study 20128284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone for 4 days along with anti-inflammatory drug
Number of subjects: 60
Study 20128284 — intervention group
Group type: COMPARATOR
Intervention: Placebo along with anti-inflammatory drug
Number of subjects: 60
Study 17729433 — intervention group
Group type: EXPERIMENTAL
Intervention: Periinterventional prophylactic antibiosis (Unacid 3 g or Ciprobay 100 mg for penicillin allergy)
Number of subjects: 164
Study 17729433 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiosis
Number of subjects: 164
Study 15042123 — intervention group
Group type: EXPERIMENTAL
Intervention: cellobiose‐[13C]ureide
Number of subjects: 8
Study 15042123 — intervention group
Group type: EXPERIMENTAL
Intervention: glucose‐[13C]ureide
Number of subjects: 8
Study 15042123 — intervention group
Group type: EXPERIMENTAL
Intervention: cellobiose‐[13C]ureide with predosing of unlabelled cellobiose ureide
Number of subjects: 8
Study 15042123 — intervention group
Group type: EXPERIMENTAL
Intervention: glucose‐[13C]ureide with predosing of unlabelled glucose ureide
Number of subjects: 8
Study 11729368 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-hirudin low dose (0.1 mg/kg bolus, 0.01 mg/kg/h infusion)
Number of subjects: 30
Study 11729368 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-hirudin intermediate dose (0.15 mg/kg and 0.015 mg/kg/h)
Number of subjects: 30
Study 11729368 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-hirudin high dose (0.2 mg/kg and 0.02 mg/kg/h)
Number of subjects: 30
Study 11729368 — intervention group
Group type: COMPARATOR
Intervention: Heparin (control group)
Number of subjects: 30
Study 9725759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0
Study 9376032 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 44
Study 9376032 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study 1837646 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (GenHevac B Pasteur) 20 micrograms administered at birth, 1 month, 2 months, and booster at 12 months; in combination with 100 IU HBIg for high risk group.
Number of subjects: 37
Study 1837646 — intervention group
Group type: COMPARATOR
Intervention: Recombinant hepatitis B vaccine (GenHevac B Pasteur) 20 micrograms administered at birth, 1 month, 2 months, and booster at 12 months; alone for low risk group.
Number of subjects: 37
Study 6751067 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 19
Study 6751067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30859691 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodized titanium oxide abutments
Number of subjects: 35
Study 30859691 — intervention group
Group type: COMPARATOR
Intervention: Control machined titanium abutments
Number of subjects: 35
Study 29410046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) treatment
Number of subjects: 104
Study 26838691 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC) with the Watchman device
Number of subjects: 0
Study 24393277 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei NCC2461 for 4 weeks
Number of subjects: 31
Study 24393277 — intervention group
Group type: COMPARATOR
Intervention: Blend of Lactobacillus acidophilus ATCC SD5221 and Bifidobacterium lactis ATCC SD5219 for 4 weeks
Number of subjects: 31
Study 23104251 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of CXCL16
Number of subjects: 248
Study 23104251 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of PTX3
Number of subjects: 248
Study 23104251 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of von Willebrand factor (vWF)
Number of subjects: 248
Study 20098960 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental stannous‐containing sodium fluoride dentifrice
Number of subjects: 31
Study 20098960 — intervention group
Group type: COMPARATOR
Intervention: Regular sodium fluoride negative control
Number of subjects: 31
Study 18797301 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantically related prime
Number of subjects: 0
Study 18797301 — intervention group
Group type: COMPARATOR
Intervention: Semantically unrelated prime
Number of subjects: 0
Study 15921805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 260
Study 15921805 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 260
Study 11912265 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 0
Study 11912265 — intervention group
Group type: COMPARATOR
Intervention: Standard Hemodialysis (HD)
Number of subjects: 0
Study 9564124 — intervention group
Group type: EXPERIMENTAL
Intervention: Information intervention
Number of subjects: 61
Study 9564124 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation intervention
Number of subjects: 61
Study 9564124 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study 7877340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure plaster of Semen Impatientis on otoacupoints
Number of subjects: 295
Study 7877340 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar cases)
Number of subjects: 295
Study 3063335 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous alizapride (3.5 mg/kg)
Number of subjects: 40
Study 3063335 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous metoclopramide (1 mg/kg)
Number of subjects: 40
Study 27599818 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program and six case conferences
Number of subjects: 140
Study 27760143 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated (150 ± 10 cGy) Pv-infected Anopheles mosquitoes (RAS)
Number of subjects: 28
Study 27760143 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated non-infected mosquitoes (Ctl)
Number of subjects: 28
Study 27760143 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-irradiated Pv-infected mosquitoes (Fy-)
Number of subjects: 28
Study 24944332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-release hydrocortisone (DR-HC) 20-40 mg once daily
Number of subjects: 64
Study 24944332 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily hydrocortisone 20-40 mg divided into three daily doses
Number of subjects: 64
Study 24944332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-release hydrocortisone (DR-HC)
Number of subjects: 64
Study 24944332 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily hydrocortisone
Number of subjects: 64
Study 22709705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (MyPyramid Menu Planner for Moms)
Number of subjects: 27
Study 22709705 — intervention group
Group type: COMPARATOR
Intervention: Minimal Care group
Number of subjects: 27
Study 20816297 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fluoride toothpaste technique (MFTT)
Number of subjects: 100
Study 20816297 — intervention group
Group type: COMPARATOR
Intervention: Routine oral hygiene instructions with fluoride toothpaste
Number of subjects: 100
Study 18472682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure goal (mean arterial pressure [MAP] of 92 mm/Hg or lower)
Number of subjects: 0
Study 18472682 — intervention group
Group type: COMPARATOR
Intervention: Usual blood pressure goal (MAP of 102-107)
Number of subjects: 0
Study 18472682 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (randomized drug assignments)
Number of subjects: 0
Study 18472682 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (baseline characteristics)
Number of subjects: 0
Study 18472682 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (income status)
Number of subjects: 0
Study 16167793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 21 microg x hr(‐1) with ropivacaine
Number of subjects: 58
Study 16167793 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 11 microg x hr(‐1) with ropivacaine
Number of subjects: 58
Study 16167793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 12873958 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic solution with epinephrine (Group E)
Number of subjects: 110
Study 12873958 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic solution without epinephrine (Group P)
Number of subjects: 110
Study 10584882 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART)
Number of subjects: 615
Study 10584882 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 615
Study 8917260 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training for 6 months (lumbar extension exercise performed 1 day/week and variable resistance exercises performed 2 days/week)
Number of subjects: 16
Study 8917260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no resistance exercise)
Number of subjects: 16
Study 1615615 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of cefadroxil once a day for three days
Number of subjects: 362
Study 1615615 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of nitrofurantoin three times a day for three days
Number of subjects: 362
Study 1615615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 6228746 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-vinyl GABA, 2 g/day
Number of subjects: 6
Study 6228746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31780017 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa 5% gel
Number of subjects: 62
Study 31780017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 29466116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 15
Study 29466116 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 15
Study 27436275 — intervention group
Group type: COMPARATOR
Intervention: Exenatide QW 2 mg (self-administered)
Number of subjects: 121
Study 27436275 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QMS 5 mg (caregiver-administered)
Number of subjects: 121
Study 27436275 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QMS 8 mg (caregiver-administered)
Number of subjects: 121
Study 27436275 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QMS 11 mg (caregiver-administered)
Number of subjects: 121
Study 24831438 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified oral food challenge with doses of roasted peanuts ranging from 3 to 4500 mg of peanut protein
Number of subjects: 63
Study 24831438 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified oral food challenge
Number of subjects: 63
Study 22383993 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (anti-IL-2Rα monoclonal antibody), given during lymphodepleting temozolomide (TMZ) treatment
Number of subjects: 6
Study 22383993 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 6
Study 22383993 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 6
Study 20920802 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Sanyinjiao point
Number of subjects: 86
Study 20920802 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 86
Study 17397924 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy with phacoemulsification
Number of subjects: 40
Study 17397924 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C and phacoemulsification
Number of subjects: 40
Study 16143126 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine 200 microg daily
Number of subjects: 267
Study 16143126 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 267
Study 16143126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 11880968 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir-containing regimen (with zidovudine and lamivudine)
Number of subjects: 32
Study 11880968 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir-containing regimen (with zidovudine and lamivudine)
Number of subjects: 32
Study 11880968 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (indinavir or nelfinavir with zidovudine and lamivudine)
Number of subjects: 32
Study 10217083 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based peer counselling with six visits
Number of subjects: 130
Study 10217083 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based peer counselling with three visits
Number of subjects: 130
Study 10217083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 130
Study 10217083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (six and three visits combined)
Number of subjects: 130
Study 7477806 — intervention group
Group type: COMPARATOR
Intervention: Psychopharmacological treatment (details not provided)
Number of subjects: 137
Study 2080934 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin nasal spray (200 IU intranasal daily for one year)
Number of subjects: 36
Study 2080934 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 531075 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral methadone
Number of subjects: 3
Study 531075 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral methadone
Number of subjects: 3
Study 531075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 31225894 — intervention group
Group type: EXPERIMENTAL
Intervention: High trust
Number of subjects: 165
Study 31225894 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved or stable high trust
Number of subjects: 165
Study 28521837 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 524
Study 28521837 — intervention group
Group type: EXPERIMENTAL
Intervention: Health extension workers as information source
Number of subjects: 524
Study 28521837 — intervention group
Group type: EXPERIMENTAL
Intervention: Good knowledge of Implanon
Number of subjects: 524
Study 28521837 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive attitudes towards Implanon use
Number of subjects: 524
Study 28521837 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing Implanon use
Number of subjects: 524
Study 24973230 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG theta/beta ratio (tbr)
Number of subjects: 86
Study 24973230 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG beta-1 power
Number of subjects: 86
Study 24973230 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG beta-1 power over Broca's area
Number of subjects: 86
Study 24973230 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG theta/beta ratio (tbr) over Broca's area
Number of subjects: 86
Study 22573338 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-based email intervention targeting physical activity, 12 weeks duration
Number of subjects: 74
Study 22573338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no email messages, no e-counselor access)
Number of subjects: 74
Study 21455059 — intervention group
Group type: EXPERIMENTAL
Intervention: MP4OX
Number of subjects: 367
Study 21455059 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 367
Study 19335655 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized prevention program (n = 611, eight schools)
Number of subjects: 1466
Study 19335655 — intervention group
Group type: COMPARATOR
Intervention: Usual classes (n = 855, eight schools)
Number of subjects: 1466
Study 19335655 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized prevention program (for females)
Number of subjects: 1466
Study 19335655 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized prevention program (for males)
Number of subjects: 1466
Study 16757527 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (6 mg daily injection for 3 months)
Number of subjects: 27
Study 16757527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (self-administered for 3 months)
Number of subjects: 27
Study 15313211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial enzymatic activity study
Number of subjects: 200
Study 15313211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial DNA amplification using PCR
Number of subjects: 200
Study 11522739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked green banana (250 g/L)
Number of subjects: 62
Study 11522739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin (4 g/kg)
Number of subjects: 62
Study 11522739 — intervention group
Group type: COMPARATOR
Intervention: Rice-diet alone (control)
Number of subjects: 62
Study 9322269 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study 8280545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bromfenac 10 mg
Number of subjects: 91
Study 8280545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bromfenac 25 mg
Number of subjects: 91
Study 8280545 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine 0.2 mg
Number of subjects: 91
Study 8280545 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine 0.4 mg
Number of subjects: 91
Study 3103972 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose intake
Number of subjects: 0
Study 3103972 — intervention group
Group type: COMPARATOR
Intervention: Low glucose intake
Number of subjects: 0
Study 29377474 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (single dose prior to transplantation)
Number of subjects: 57
Study 29377474 — intervention group
Group type: COMPARATOR
Intervention: Control (no eculizumab)
Number of subjects: 57
Study 27543529 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models using clinical characteristics and central venous blood gas values
Number of subjects: 590
Study 27543529 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds of predicted variables from the derivation set
Number of subjects: 590
Study 25597173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (200 IU/d) and calcium (600 mg/d)
Number of subjects: 86
Study 25597173 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (100 mg) and vitamin C (100 mg)
Number of subjects: 86
Study 22918825 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency kyphoplasty (RFK)
Number of subjects: 181
Study 22918825 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 181
Study 20439627 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE; 0.625 mg/d)
Number of subjects: 10739
Study 20439627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study 18762911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable screw fixation
Number of subjects: 62
Study 18762911 — intervention group
Group type: COMPARATOR
Intervention: Metal screw fixation
Number of subjects: 62
Study 16881241 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment program
Number of subjects: 0
Study 16881241 — intervention group
Group type: EXPERIMENTAL
Intervention: Other programs
Number of subjects: 0
Study 16881241 — intervention group
Group type: COMPARATOR
Intervention: Passive job seekers
Number of subjects: 0
Study 12814319 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 IMZ implants placed in a single-stage procedure
Number of subjects: 60
Study 12814319 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 IMZ implants placed in the traditional 2-stage procedure
Number of subjects: 60
Study 12814319 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ITI implants (single-stage procedure)
Number of subjects: 60
Study 11010659 — intervention group
Group type: EXPERIMENTAL
Intervention: Profound condition (writing about bereavement experience)
Number of subjects: 64
Study 11010659 — intervention group
Group type: COMPARATOR
Intervention: Trivial condition (writing about innocuous topics)
Number of subjects: 64
Study 11010659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Profound and Trivial)
Number of subjects: 64
Study 8794418 — intervention group
Group type: EXPERIMENTAL
Intervention: Replens (non-hormonal moisturizing vaginal gel) applied three times a week for 12 weeks
Number of subjects: 39
Study 8794418 — intervention group
Group type: COMPARATOR
Intervention: Dienoestrol (oestrogenic vaginal cream) administered daily for the first 2 weeks and then three times a week
Number of subjects: 39
Study 1638171 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl (5 mg twice a day for 60 days)
Number of subjects: 10
Study 1638171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6465938 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 46
Study 6465938 — intervention group
Group type: COMPARATOR
Intervention: Injected adrenaline
Number of subjects: 46
Study 31076136 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurology Hat Game
Number of subjects: 121
Study 28166806 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injections in the calf muscles
Number of subjects: 96
Study 28166806 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline injections in the calf muscles (placebo)
Number of subjects: 96
Study 28003251 — intervention group
Group type: EXPERIMENTAL
Intervention: ROX coupler implantation in patients with combined hypertension (CH)
Number of subjects: 42
Study 28003251 — intervention group
Group type: EXPERIMENTAL
Intervention: ROX coupler implantation in patients with isolated systolic hypertension (ISH)
Number of subjects: 42
Study 24861802 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus weekly post‐discharge breastfeeding telephone support (20-30 minutes for 4 weeks)
Number of subjects: 722